Lab Automate has developed and globally patented the A3G technology which can reduce the time to market of Inhalation products by up to 25%. The technology’s feasibility has been independently proven by tests done at Cirrus Pharmaceuticals and by University of Maryland. The technology has a $2.8 billion market which is growing @ 6%/annum. Expects to be profitable in 2nd year with 5th year sales projected @$50MM--is seeking $1.3MM to develop commercial scale equipment.

2012 Boston Gold Winner